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INTRODUCTION
Spontaneous occlusion of the circle of Willis, first described
as Moyamoya disease in Japan, is characterized by bilateral
stenosis and/or occlusion of the terminal portion of the inter-
nal carotid artery and by the development of abnormal net-
like vessels at the base of the brain (1). There are remarkable
regional differences in the incidence of Moyamoya disease.
Moyamoya disease is mostly found in Asians and rare in
Caucasian (2). Moyamoya disease is known to be prevalent
in children under 10 yr old and young adults in the third
decade and occurs more frequently in females (male to female
ratio of 2:3) (3). In an epidemiological survey of Moyamoya
disease in Korea, the overall clinical background was similar
to that of Japanese patients, although Korean Moyamoya
disease showed a relatively higher incidence of hemorrhage
and adult onset (4-7).
Previous investigations suggested some hypotheses to
explain the etiology of Moyamoya disease, such as infection
in the upper respiratory tract (8), influence of immune sys-
tem (9), thrombogenesis on the intima (10, 11), and disor-
der of the vascular smooth muscle cell (12-14). An epidemi-
ological study showed that Moyamoya disease might be
caused by genetic factors rather than environmental factors
(15). However, the role of genetic factors in the pathogene-
sis had not been completely clarified yet. 
Human leukocyte antigen (HLA) molecules play an impor-
tant role in the immune system, which present peptides
derived from self and foreign antigens to appropriate T lym-
phocytes. The alleles of HLA molecules have been reported
to be frequently strongly associated with various diseases,
such as autoimmune disease, infectious disease, and virus-
associated tumor. Therefore, the identification of the associ-
ation between HLA and disease susceptibility has become
important to diagnose and understands the pathogenesis of
the disease. Previous studies reported that Moyamoya dis-
ease was associated with some HLA alleles (16, 17). But the
studies of HLA association of Moyamoya disease have been
very limited to only Japanese. Recently, some reports have
suggested possible linkage with Moyamoya disease on chro-
mosome 3p24.2-p26 and 17q25 (18, 19). And the marker
located on chromosome 6 was also suggested to be in link-
age with Moyamoya disease (20).
In this study, we investigated the distributions of HLA
alleles in 28 Korean patients with Moyamoya disease to
identify HLA markers that may contribute to the genetic
susceptibility to Moyamoya disease in the Korean popula-
tion.
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Associations of Moyamoya Patients with HLA Class I and Class II
Alleles in the Korean Population
Moyamoya disease is characterized by progressive cerebrovascular occlusion at
the peripheral internal carotid artery and development of abnormal collateral circu-
lation at the cerebral basal region. Although abnormal thrombogenesis, inflamma-
tion and autoimmune process might be involved in the etiology, the genetic patho-
genesis of Moyamoya disease is still unknown. To evaluate the association of
Moyamoya disease with HLA alleles in the Korean population, we investigated
HLA class I and class II alleles in 28 Moyamoya patients and 198 unrelated healthy
controls. The frequency of HLA-B35 allele was significantly increased in the
patients compared to the controls (32.1% vs. 10.1%, RR=4.2, p<0.008). Further
analysis of HLA-B35 on onset age and sex showed that this allele was significant-
ly increased compared to the controls in both late-onset and female group. Espe-
cially, HLA-B35 was the most significantly increased in female of late-onset group
compared to the controls. These results suggest that HLA-B35 may be an useful
genetic marker for Moyamoya disease, and particularly in females of late onset
group in the Korean population.
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MATERIALS AND METHODS
Subjects
Twenty-eight Korean patients with Moyamoya disease
(11 men and 17 women) who were diagnosed as definite
Moyamoya disease according to the criteria for Moyamoya
disease were involved in this study. The subjects were col-
lected from 1992 to 2001 at the Neurosurgery Service of
Uijongbu St. Mary’s Hospital, Uijongbu, Korea. The ages
of the patients ranged from 2 to 68 yr. Their results were
compared with those of the control group, which was com-
posed of 198 Korean drawn from the healthy normal popu-
lation.
HLA-A, B serology typing
Peripheral blood (10 mL) was collected using anticoagu-
lant treated Vacutainer (Becton Dickinson Vacutainer sys-
tems, Franklin Lakes, NJ, U.S.A.) and mononuclear cells
were isolated by density gradient centrifugation on a Ficoll-
Hypaque (Pharmacia Biotech, Wikstoms, Sweden). HLA-A
and -B typing was done according to a standard microlym-
phocytotoxicity technique (21). Cells and serum were incu-
bated together for 30 min at 25℃and incubated at 25℃for
1 hr by the addition of complement. Cell death was assessed
by the addition of Eosin-Y and read on a microscope. The
standard nomenclature system was followed throughout to
describe the HLA alleles.
HLA-B genotyping
To confirm the serological results of HLA-B, we applied
molecular approach (ARMS-PCR; Amplification refractory
modification system-polymerase chain reaction) for geno-
typing of HLA-B in this study. DNA was extracted from
heparinized blood by the salting out method and HLA-B
typing was performed by the ARMS-PCR method described
by Bunce et al. and Tonks et al. (22, 23). Each tube con-
tained a primer mix consisting of the allele- or group-spe-
cific primer pairs as well as a positive control primer, which
matched the non-allelic sequences. PCR reactions were per-
formed in a volume of 7  L, as modified in the class I ARMS-
PCR reference manual of the 12th International Histocom-
patibility Workshop. PCR product size was defined on 1.5%
agarose gel prestained with ethidium bromide.
HLA class II Genotyping
HLA class II typing was performed by the PCR-SSOP
(sequence specific oligonucleotide probe) method, which was
essentially the same as that described at the 12th International
Workshop, with minor modifications (24). For each locus,
specific primers were used to amplify products, which were
then denatured and immobilized on a nylon membrane and
probed with a series of digoxigenin labeled oligonucleotides
specific for the known hyper-variable sequences. Stringent
washing was performed in the presence of tetramethyl ammo-
nium chloride (TMAC, Sigma Chemical Co. St. Louis, MO,
U.S.A.). The hybridized probe was detected according to the
manufacturer’s instructions with the anti-digoxigenin anti-
body conjugated with alkaline phosphatase and followed by
the addition of chemiluminescent substrate CSPD (Boehringer
Mannheim, GmbH, Germany). Chemiluminescence was
detected by exposure to radiography film. 
Statistical Analysis  
The odds ratio was calculated with Woolf’s formula and,
by convention, expressed as a relative risk (RR). Haldane’s
modification of the formula was used when one element of
the equation was zero (25). The statistical significance of the
difference was tested by chi-square test with 1 degree of free-
dom or by the 2-tailed Fisher’s exact test when the criteria
for the chi-square test were not fulfilled. Generally, p values
less than 0.05 were considered statistically significant.
RESULTS
Association of HLA class I and class II alleles in
Moyamoya Disease
The frequencies of HLA-A and B alleles in patients with
Moyamoya disease and normal controls are shown in Table
1. The frequency of HLA-B35 was significantly increased in
the patients compared with controls (32.1% vs. 10.1%:
Moyamoya patients vs. controls, RR=4.2, p<0.008). How-
ever, there were no significant differences between the patients
and controls in the frequencies of HLA-A and other B alle-
les. Table 2 shows the frequencies of HLA-DRB1, -DQA1,
and -DQB1 alleles in patients with Moyamoya diseases and
normal controls. However, there were no significant differ-
ences between the patients and controls in the Korean pop-
ulation. 
Distribution of HLA phenotype frequency according to
onset age
The average age at onset of the subject in this study is 34 yr.
Previous study showed that Moyamoya disease in the Korean
population might be classified into two groups, below and
above 10-yr at onset (4). Therefore, we divided the patients
into two groups according to the age at onset 10 yr, early and
late onset group. The frequency of HLA-B35 in late-onset
group was significantly increased compared with controls
(40.9% vs. 10.1%: Moyamoya patients vs. controls, RR=6.2,
p<0.002) (Table 3). Interestingly, HLA-B35 was not appeared
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in early onset group, although the significant difference of
the frequency between early and late onset group was not
shown, probably due to small number of patients.
Distribution of HLA phenotype frequencies according
to gender
When the distributions of HLA alleles were compared
between female and/or male and controls, the frequency of
HLA-B35 was also found to be higher in female patients
than controls (47.1% vs. 10.1%: Moyamoya patients vs. con-
trols, RR=7.9, p<0.0007) (Table 3). Although the significant
differences between female and male were not shown, the
frequency of HLA-B35 was increased in female than male.
Especially, HLA-B35 was the most significantly increased in
female of late onset group compared with controls (53.3% vs.
10.1%: Moyamoya patients vs. controls, RR=10.2, p<0.0003)
(Table 3).
DISCUSSION
Moyamoya disease is characterized by progressive cere-
brovascular occlusion at the peripheral internal carotid artery
and development of abnormal collateral circulation at the
cerebral basal region (8, 26). The pathogenesis of Moyamoya
disease is still unknown, although several reports suggested
that abnormal thrombogenesis, inflammatory process and
autoimmune process might be involved in the etiology. 
Human leukocyte antigen, presenting peptides derived
from self and foreign antigens to T lymphocytes, plays an
important role in the immune system. HLA disease associa-
tions are of diagnostic and prognostic importance because
the presence of certain HLA alleles can raise the risk of devel-
oping certain disorders and in specialized situations this
*: RR=4.2, p<0.008.
HLA-B HLA-A
Moyamoya 
patients 
n=28 (%)
Normal 
controls 
n=198 (%)
Moyamoya
patients 
n=28 (%)
Normal
controls
n=198 (%)
1 0 5 (2.5) 7 2 (7.1) 14 (7.1)
2 13 (46.4) 94 (47.5) 8 0 2 (1.0)
3 1 (3.6) 8 (4.0) 13 3 (10.7) 15 (7.6)
11 6 (21.4) 44 (22.2) 14 1 (3.6) 9 (4.5)
24 10 (35.7) 68 (34.3) 27 0 12 (6.1)
26 6 (21.4) 22 (11.1) 35 9 (32.1)* 20 (10.1)
29 1 (3.6) 0 37 0 2 (1.0)
30 2 (7.1) 19 (9.6) 38 0 4 (2.0)
31 4 (4.3) 24 (12.1) 39 0 1 (0.5)
32 0 2 (1.0) 42 1 (3.6) 0
33 9 (32.1) 77 (38.9) 46 2 (7.1) 22 (11.1)
48 2 (7.1) 8 (4.0)
51 2 (7.1) 30 (15.2)
52 1 (3.6) 9 (4.5)
54 1 (3.6) 30 (15.2)
55 1 (3.6) 9 (4.5)
57 0 1  (0.5)
58 6 (21.4) 29 (14.6)
59 3 (10.7) 6 (3.0)
60 2 (7.1) 16 (8.1)
61 7 (25.0) 46 (23.2)
62 6 (21.4) 41 (20.7)
67 0 4 (2.0)
75 0 3 (1.5)
Table 1. Comparisons of HLA-A and B alleles between Moya-
moya patients and healthy normal controls
Moyamoya patients
n=28 (%)
Normal controls
n=198 (%)
DRB1
01 1 (3.6) 26 (13.1)
15 7 (25.0) 38 (19.2)
16 0 4 (2.0)
11 2 (7.1) 9 (4.5)
12 11 (39.3) 68 (34.3)
13 2 (7.1) 24 (12.1)
14 3 (10.7) 24 (12.1)
03 6 (21.4) 53 (26.8)
04 6 (21.4) 32 (16.2)
07 4 (14.3) 18 (9.1)
08 5 (17.9) 40 (20.2)
09 5 (17.9) 33 (16.7)
10 0 6 (3.0)
DQA1
01 17 (60.7) 146 (73.7)
02 4 (14.3) 18 (9.1)
03 16 (57.1) 106 (53.5)
04 2 (7.1) 6 (3.0)
05 7 (25.0) 45 (22.7)
06 1 (3.6) 9 (4.5)
DQB1
02 6 (21.4) 23 (11.6)
03 17 (60.7) 111 (56.1)
04 9 (32.1) 42 (21.2)
05 7 (25.0) 63 (31.8)
06 14 (50.0) 104 (52.5)
Table 2. Comparisons of HLA-DRB1, DQA1, and DQB1 alleles
between Moyamoya patients and healthy normal controls
Comparison Clinical character HLA-B35
Onset Early-onset (10<=) n=6 (%) 0
Late-onset (10>) n=22 (%) 9 (40.9)*
Sex Male, n=11 (%) 1 (9.1)
Female, n=17 (%) 8 (47.1)
�
Early onset Male, n=4 (%) 0
Female, n=2 (%) 0
Late onset Male, n=7 (%) 1 (14.3)
Female, n=15 (%) 8 (53.3)
�
Normal Controls, n=198 (%) 20 (10.1)
*: RR=6.2, p<0.002, 
� : RR=7.9, p<0.0007, 
� : RR=10.2, p<0.0003.
Table 3. Comparison of HLA-B35 in Moyamoya patients accord-
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information can be helpful. Previous studies reported that
Moyamoya disease was associated with some HLA alleles.
Aoyagi et al. found a significant association of HLA-B51 in
their investigation of 32 unrelated Japanese patients with
Moyamoya disease (16). Takuya et al. showed that HLA-
DRB1*0405, DQB1*0502, and *0401 had significant asso-
ciation with Moyamoya disease in Japanese (17). In this study,
we found that the frequency of HLA-B35 was significantly
increased in the patients compared with controls (Table 1).
We performed molecular approach (ARMS-PCR) for geno-
typing of HLA-B and confirmed the serological results of
HLA-B. Several studies showed that HLA-B35 might be
associated with autoimmune and infectious diseases (27, 28).
Previous reports suggested that virus and bacterial infection
might be involved in the pathogenesis of Moyamoya disease
(29, 30) and the autoimmune antibody was recognized more
frequently in patients with Moyamoya disease (31). Thus,
HLA-B35 may have direct influences on the pathogenesis
of Moyamoya disease in some aspects of inflammatory or/and
autoimmune process. We did not find a significant associa-
tion of HLA-B51, DRB1*0405, DQB1*0502, and *0401
although theses alleles were reported to be significantly asso-
ciated with Moyamoya patients in Japanese (16, 17) which
are genetically and clinically similar to Koreans. Therefore,
these results suggest that the association between HLA anti-
gens and Moyamoya disease may differ between ethnic groups
and these different HLA alleles may not be significant sus-
ceptibility factors associated with Moyamoya disease, but
only genetic marker. Further studies are required to evalu-
ate the more detailed genetic aspects of Moyamoya disease.
Moyamoya disease was reported to occur more frequently
in females and be prevalent among patients <10 yr of age
(3, 4). In this study, we analyzed the distributions of HLA
alleles according to age at onset and sex. HLA-B35 in both
late onset and female group was significantly increased com-
pared with controls. Especially, HLA-B35 was the most sig-
nificantly increased in female of late onset group compared
with controls (Table 3). Therefore, these results suggest that
HLA-B35 may be a more useful genetic marker for Moyamoya
in females, and particularly in females of late onset group in
the Korean population. In conclusions, we demonstrated the
associations of Moyamoya disease with specific HLA allele
in the Korean population. Further studies including family
will be required to confirm these data and to investigate new
genes associated with Moyamoya disease.
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